Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ouch, what's quick drop for?
Usually comments & Q/A sessions aren't kept in playback of cc :(
Anyone recording the JPM cc ? I wouldn't mind hearing it, but at work and can't get on phone for while
News for 'ESPI' - (ESP Resources, Inc. Reports Financial Results for the First Quarter Ended March 31, 2011)
SCOTT, La., May 17, 2011 (GlobeNewswire via COMTEX) -- ESP Resources, Inc.
(OTCBB:ESPI) (the "Company" or "ESP Resources"), a manufacturer, blender,
distributor, and marketer of specialty chemicals and analytical services to the
oil and gas industry, announced unaudited financial results for the quarter
ended March 31, 2011.
Revenue for three months ended March 31, 2011 was $1,815,156, compared to
$1,015,576 for the same period in 2010, an increase of $799,580, or 79%. The
increase was due to several factors including the expanded customer base from
increased sales coverage in the Southern Louisiana, South Texas, East Texas and
Arkansas regions. The Company hired additional field service technicians in the
South Texas and Arkansas regions in previous quarters and their sales contacts
resulted in a direct increase in sales volumes from these regions. In addition,
sales volume increased to several of the Company's existing customers through
supply of additional petrochemical products at its customer well-sites.
Gross profit as a percentage of revenue was 43% for the three months ended March
31, 2011, as compared to 46% for same period in 2010. The 3% decrease was the
result of significantly increased equipment sales at new wells for several of
the Company's customers which have a lower margin than the Company's custom
designed chemical sales.
General and administrative expenses, net of depreciation and amortization,
increased by $706,864 for the three months ended March 31, 2011, compared to the
same period last year. The increase was primarily due to the increase in staff
and additions of new facilities in the Company's Longview, Texas and Guy,
Arkansas regions. The Company's personnel level increased from nineteen (19)
employees in 2010 to twenty-seven (27) employees in 2011 to accommodate the
increase in sales.
Net loss was $839,464 for the three months ended March 31, 2011, compared to a
loss of $426,985 for the same period in 2010. The increase for the period was
due to an increase in service and operations expenses as the Company continues
to expand into new sales regions and add further infrastructure to support
higher levels of sales in future periods.
Commenting on the results, Mr. David Dugas, President of ESP Resources, Inc.,
stated, "While we are excited about our continued sales growth, we are also
pleased that we are now adequately staffed to be able to support new customers
and the growing needs of our existing customer base. Investing in personnel to
deliver consistent and superior service to our customers is of paramount
importance as we drive sales," Mr. Dugas stated further.
About ESP Resources, Inc.:
ESP Resources, Inc. is a publicly-traded petrochemical company (OTCBB:ESPI)
headquartered in Scott, LA. Through its wholly owned subsidiary, ESP
Petrochemicals, Inc., the Company manufactures, blends, distributes and markets
specialty chemicals and analytical services to the oil and gas industry. ESP
Resources supplies retail and wholesale specialty chemicals for a variety of oil
field applications including production, drilling, waste remediation, cleaning,
and waste water treatment. From its blending and distribution facilities, the
Company distributes its product line throughout the oil and gas producing
regions of Louisiana, Texas, Mississippi, Alabama, Arkansas and Oklahoma, both
onshore and offshore. The wholesale division of the Company supplies specialty
chemicals to several retailers operating in West Africa. The Company's senior
management has over 100 years of combined operating experience in the
petrochemical industry. More information is available on the Company's Website
at www.espchem.com.
Legal Notice Regarding Forward-Looking Statements:
This press release contains "forward looking statements" within the meaning of
the safe harbor provisions of the U.S. Private Securities Litigation Reform Act
of 1995. Statements in this news release that are not historical facts are
forward-looking statements that are subject to risks and uncertainties.
Forward-looking statements are based on current facts and analyses and other
information that are based on forecasts of future results, estimates of amounts
not yet determined and assumptions of management. Forward looking statements are
generally, but not always, identified by the words "expects," "plans,"
"anticipates," "believes," "intends," "estimates," "projects," "aims,"
"potential," "goal," "objective," "prospective," and similar expressions or that
events or conditions "will," "would," "may," "can," "could" or "should" occur.
Information concerning oil or natural gas reserve estimates may also be deemed
to be forward looking statements, as it constitutes a prediction of what might
be found to be present when and if a project is actually developed. Actual
results may differ materially from those currently anticipated due to a number
of factors beyond the reasonable control of the Company. It is important to note
that actual outcomes and actual results could differ materially from those in
such forward-looking statements.
Readers are cautioned not to place undue reliance on the forward-looking
statements made in this press release. In evaluating these statements, you
should consider the risks discussed, from time to time, in the reports we file
with the U.S. Securities & Exchange Commission. For a discussion of some of the
risks and important factors that could affect the Company's future results and
financial condition, see the Company's Form 10-Ks and 10-Qs on file with the
U.S. Securities & Exchange Commission.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: ESP Resources, Inc.
By Staff
CONTACT: CONTACT: David Dugas, President
ESP Resources, Inc.
david.dugas@espchem.com
(337) 706-7056
(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.
-0-
INDUSTRY KEYWORD: Business Services
SUBJECT CODE: OIL
CHEMICALS
EARNINGS
Earnings Releases and Operating Results
Not sure who all listened to the conference call the other day. My network access (through phone online) was in/out but did hear some very good points.
When asked about being under $1 in stock price. Company stated that they were doing nothing at this time (almost like they expected it to be above $1 by September) but were not ruling out a possible reverse split or other means to get back up and also OTC BB could be a possibility. My take was once P3 starts, company will have plenty of good news to give out and we'll be above $1 anyway...
Also on Menerba - so far seems totally safe and WORKS like it's supposed to. This is very low risk considering hormone therapy. It was stated even if they only got 2% of the market Menerba could be a BILLION DOLLAR DRUG.
They are looking at partnership based upon performance. Get some $$$ now, then partner could buy in larger once drug is proven.
Everything besides Menerba is on hold right now to preserve capital, which is expected to last til first quarter next year
If anyone taped the whole question/answer on the call, I'd like to have a copy of it to re-listen to, as the one online doesn't have Q & A session.
Think as we get closer to 3rd quarter we'll be well over $1 after listening to that conf call regarding earnings! Bright future here
Nice buying this morning, glad I picked some up couple weeks ago!
You're comparing OTC-BB to non-reporting pinkie? And I'm sure JAMN's biz isn't just renting a pizza oven from the CEO of the shell you (err, I mean shareholders) just purchased AGAIN...
I like how you said that "I bet you this pizza parlor makes more money in real business then 99.9% of other triple zero sub-penny stocks."
Now let's take a look at what I really think about that comment
"I bet you this pizza parlor makes more money in real business then 99.9% of other triple zero sub-penny stocks."
There is a reason stocks go to .000 & sub penny and that's NOT because there are real fundamentals behind it making $$$. Usually it's dilution and they only get back up with either a very good pump job with very limited dilution, or reverse split... This one seems to have already shown it's willing to dilute into any movement, so what ya got left?
Then they were paid twice because I believe they also got a nice little deal on Corus bank from the FDIC!
Yeh, I'd rather of seen 600 shareholders objecting to the same document rather than sending the same things each time...
Don't like being out and want back in, huh?
There is ONLY 1 single location in Sacketts Harbor NY called "Mariono's Pizza"... They rent enough space to make the pizzas from a bakery located there that Tom Scozzafava is involved with. This shell is an ex-Scozzafava shell.
Search his name before wasting your cash!
I'd rather just see equity get back what they lost than worry about his sorry @ss spending jail time.
Give me mine! NOOOOOOOOOWWWWWWWWWWWW
Over 10% of the OS short and climbing! Need a catalyst to take off
I like this sentence... very well done sir!
Also remember, JPM may very well have known of the insider trading and instead of reporting it to the authorities extracted favorable gsa terms for itself for jpm's silence....
Exactly... If the EC needed more leverage, they wouldn't have accepted a third postponement.
HF's have info on JPM/FDIC. Between the HF's/JPM/FDIC we're looking at a nice little perk soon. The current POR will not stand, there will be additional "Asset Valuation" and all of Equity will get back some of what they've lost.
Apparently Menerba has been shown to be totally safe and works! Was stated on the call that even if they ONLY get 2% of the market, it's a billion dollar drug!
They were asked about a reverse split. Company said there is no reason to worry about stock price now as they have until September to get back above $1 and if for some reason not there they will worry about it at that time. Looks like limited downside here and alot of upside potential!
Guess that depends on whether JPM/FDIC were actually planning with the hedgies to wipe equity out.
Like the "well these assets are hard to prove value on, but these are easy so we will trade". You wipe equity and end up with this...
Now, how many during these meetings do you think the fdic/jpm stated if you.don't.give us this equity sticks around... we all know jpm wanted shareholders to end.up with nothing!
The real money is to be made with the cash and NOL's... who gives a crap about a $20 mil subsidiary when they can wipe out shareholders with "no value" NOLs and a large cash position to utilize them in?
Just my opinion but I believe from day one commons were to be toast. They just couldn't help being greedy pigs and have gotten caught with their hand in the cookie.jar!
Earnings call sounded great what I could hear of it, kept losing my data connection... I believe we will have some green coming!
Anyone ready for some UPSIDE?
Top 10 Micro Cap Stocks with Highest Upside: BNVI, CBC, MEG, APT, JTX, DSTI, KAD, QTWWD, CRTP, MRNA (May 11, 2011)
Best-Rated Chinese Stocks; Highest-Upside; Fastest-Growing; Top 10 Lists; Analyst Actions
Below are the top 10 Micro Cap stocks with highest upside potential, UPDATED TODAY before 4:30 AM ET, based on the difference between current price and Wall Street analysts' average target price. One Chinese company (CRTP) is on the list.
http://www.cnanalyst.com/2011/05/top-10-micro-cap-stocks-with-highest-upside-bnvi-cbc-meg-apt-jtx-dsti-kad-qtwwd-crtp-mrna-may-11-201.html
Bionovo Inc. (NASDAQ:BNVI) has the 1st highest upside potential in this segment of the market. Its upside is 1150.0%. Its consensus target price is $7.50 based on the average of all estimates. Capitol Bancorp Ltd. (NYSE:CBC) has the 2nd highest upside potential in this segment of the market. Its upside is 1076.5%. Its consensus target price is $2.00 based on the average of all estimates. Media General, Inc. (NYSE:MEG) has the 3rd highest upside potential in this segment of the market. Its upside is 1000.0%. Its consensus target price is $55.00 based on the average of all estimates. Alpha Pro Tech, Ltd. (AMEX:APT) has the 4th highest upside potential in this segment of the market. Its upside is 654.3%. Its consensus target price is $8.75 based on the average of all estimates. Jackson Hewitt Tax Service Inc. (NYSE:JTX) has the 5th highest upside potential in this segment of the market. Its upside is 597.7%. Its consensus target price is $1.50 based on the average of all estimates.
DayStar Technologies Inc. (NASDAQ:DSTI) has the 6th highest upside potential in this segment of the market. Its upside is 562.3%. Its consensus target price is $5.00 based on the average of all estimates. Arcadia Resources, Inc. (AMEX:KAD) has the 7th highest upside potential in this segment of the market. Its upside is 553.8%. Its consensus target price is $0.85 based on the average of all estimates. Quantum Fuel Systems Technologies (NASDAQ:QTWWD) has the 8th highest upside potential in this segment of the market. Its upside is 537.4%. Its consensus target price is $22.50 based on the average of all estimates. China Ritar Power Corp. (NASDAQ:CRTP) has the 9th highest upside potential in this segment of the market. Its upside is 525.0%. Its consensus target price is $10.00 based on the average of all estimates. Marina Biotech, Inc. (NASDAQ:MRNA) has the 10th highest upside potential in this segment of the market. Its upside is 513.2%. Its consensus target price is $3.25 based on the average of all estimates.
Dumpage again today? Lol
I feel the Justice Dept is only going after the smaller fish to get them out of the way for the big fish... They aren't going to go after the Goldman Sachs or JPM's of the world. Just like they're doing with the current banks, get rid of the little and those assets go to the big! You know, get rid of some to help the friendly ones out...
I'd love to see JPM's trading records on Wamu while they knew the FDIC was going to seize anyway... I don't think that would ever happen though.
Some people just feel if they can suck enough bagholders in, they may just be able to get out with less loss than they're facing right now... I believe he was here when it was over .001 and if so he's facing a 90% loss at the moment, at least trying to get 30-40% of that loss back?
I believe this PR was prior to them increasing the OS 25%.. You tell me, what's significant dilution?
They stated prior to this that they were cancelling 1.81 billion shares and the OS would be 1.3 billion, now the OS is around 2 billion and there was not significant dilution?
Read between the lines... We do not SEE & NO PLANS TO
Of course his protoge "expected significant dilution to subside soon" while signing 9 cd's. Anyone that's Scozzafava taught can't put out a PR with ACTUAL FACTS and not using the "if everything goes this way" approach. If he'd said "There will be no more than xx dilution" and "There will NOT be a reverse split" then I'd bow my head and go away. To be so OPEN with possibilities and not actually say anything means nothing. Sorry that you have so much invested here, but to me seems like a POS
They did a PR on it because of the need to sell shares... Why else do the penny stock scams do pr's? How often do you see a penny stock do a PR that isn't directly related to selling shares?
think he is stating WG&M is for their clients which are for the hedge funds...
He may not be the pig you think he is
Appears to me the guy can't even run 1 pizza location.. How do you think he could handle multiple? He's on his 3rd pizza joint and still doesn't have a winner... Or do you think because of the name "Mariano's" will make this any different from the first two?
Let me ask this... What happened to the original Crescent's pizza? Now, what happened to Maury's second location he closed to open in the bakery as information shows?
First Quarter Financials tomorrow... what's the expectation?
Link Here
Independent Investigator Initiates Phase 1 Study of Biodel's Ultra-Rapid-Acting Insulin Formulations in Patients Using Insulin Pumps
DANBURY, Conn., May 10, 2011 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) announced today that an independent investigator initiated a pump trial of Biodel's two ultra-rapid-acting formulations of recombinant human insulin.
The formulations, BIOD-105 and BIOD-107, are designed to result in more rapid insulin action compared to currently marketed mealtime insulin analogs. This study is designed as a double blinded, three-period cross over trial in which insulin pumps will be used to deliver BIOD-105, BIOD-107 and Humalog® each at separate dosing visits in approximately 8 patients with type 1 diabetes. This study, expected to be completed in the fourth calendar quarter of 2011, will evaluate pharmacokinetic, pharmacodynamic and injection site tolerability profiles of BIOD-105 and BIOD-107 relative to that of Humalog®. Drs. W. Kenneth Ward and Jessica Castle of the Division of Endocrinology, Diabetes, and Clinical Nutrition at Oregon Health and Sciences University will serve as principal investigators for this trial.
Insulin pump therapy, also known as continuous subcutaneous insulin infusion (CSII), is used as a means to provide intensive insulin therapy to patients with diabetes. Currently available prandial insulins are used in pumps, but often are not absorbed rapidly enough to achieve optimal mealtime glucose control. It is believed that an ultra-rapid-acting insulin will be better suited for pump therapy than currently marketed mealtime insulin analogs.
"We look forward to evaluating BIOD-105 and BIOD-107 in insulin pump patients," said Dr. W. Kenneth Ward. "An insulin with faster absorption has the potential to better match insulin delivery with the rapid need for insulin following meals. Such an insulin might not only allow for better glucose control with today's insulin pumps but may also help lead to a functional artificial pancreas system, in which insulin delivery is automated based on minute to minute changes in blood glucose levels."
"In the third week of March we initiated a study of similar design to Dr. Ward's study in which BIOD-105, BIOD-107 and Humalog® are delivered by standard injection," said Dr. Alan Krasner, Chief Medical Officer of Biodel. "The results of both studies will help choose the best candidate for further development. We look forward to receiving these data."
About Biodel Inc.
Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes that may be safer, more effective and more convenient for patients. We develop our product candidates by applying our proprietary formulation technologies to existing drugs in order to improve their therapeutic profiles. For further information regarding Biodel, please visit the company's website at www.biodel.com.
Safe-Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements about future activities related to the clinical development plans for the company's drug candidates, including the potential timing, design and outcomes of clinical trials; and the company's ability to develop and commercialize product candidates. Forward-looking statements represent our management's judgment regarding future events. All statements, other than statements of historical facts, including statements regarding our strategy, future operations, future clinical trial results, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. The words "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The company's forward-looking statements are subject to a number of known and unknown risks and uncertainties that could cause actual results, performance or achievements to differ materially from those described or implied in the forward-looking statements, including, but not limited to, our ability to respond to the complete response letter regarding our new drug application for Linjeta™ in a timely manner and the possibility that information we provide in response to the letter may not be accepted by the FDA; our ability to secure FDA approval for Linjeta™ and our other product candidates under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act; our ability to market, commercialize and achieve market acceptance for product candidates developed using our VIAdel™ technology; the progress or success of our research, development and clinical programs and the initiation and completion of our clinical trials; the possibility that patients taking Linjeta™ may experience more injection site discomfort than they experience with competing products; unexpected data that may result from our clinical trials and our research and development activities; our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others; our estimates of future performance; our ability to enter into collaboration arrangements for the commercialization of our product candidates and the success or failure of those collaborations after consummation, if consummated; the rate and degree of market acceptance and clinical utility of our products; our commercialization, marketing and manufacturing capabilities and strategy; our estimates regarding anticipated operating losses, future revenues, capital requirements and our needs for additional financing; and other factors identified in our most recent annual report on Form 10-Q for the quarter ended March 31, 2011. The company disclaims any obligation to update any forward-looking statements as a result of events occurring after the date of this press release.
BIOD-G
CONTACT: Seth Lewis, +1-646-378-2952
I was under the impression you and your "WHALES" were going to buy up the float? Didn't you say there were some BIG buyers hitting the ask?
I agree 100% with everything you've said... Although we are just the little people! These large banks/hedge funds are so intertwined with everything else, no one wants to go against them for fear of losing their money ticket.
If only the Country utilized the constitution it was founded upon
Eh, I'm sure Bair has enough cash to live comfortably the rest of her life... No reason to work is there?
JPMorgan Chase Nearly Doubles Commodities Trading
Published: Friday, 6 May 2011 | 3:07 PM ET Text Size By: John Carney
Senior Editor, CNBC.com
CNBC.com
JP Morgan Chase
--------------------------------------------------------------------------------
The size of JPMorgan Chase’s trading portfolio of physical commodities nearly doubled from the first quarter of last year to the most recent quarter, according to filings with the SEC.
JPMorgan [JPM 44.72 -0.32 (-0.71%) ] said it had owned in its trading book of physical commodities worth around $19.5 billion as of March 31, 2011. That contrasts with just $10.5 billion for the first quarter of 2010.
Most of that growth came during the first quarter. At the end of last year, JP Morgan said it had $12 billion in physical commodities.
The commodity derivatives book is also growing. For the first quarter, the bank said it had $12.8 billion of commodity derivative assets, compared with $6.5 billion last year.
JPMorgan’s liabilities for commodities derivatives grew at an almost startling pace. In the first quarter of this year, it says it had $11.3 billion of liabilities for commodities derivatives. The year before, that number was just $2.7 billion.
Yes... I can already see this being the next PAPA JOHNS - And to think they're only starting out in a .0001 shell with about 2,000,000,000 Shares Outstanding and at miniumum another $250k in cd debt after the initial $135k cd. But don't worry, I'm sure Maury is out scouring the Country trying to find prifitable pizza locations to offer 1 BILLION shares each for on acquisitions... After all, it's not his money and shareholders can be washed/rinsed/recycled!
You do realize that $135k shareholders paid to Tom to basically buy the shell for Maury amounts to more than it would have cost him to open 10 different little hole in the wall pizza joints... And 99.9995% of successful franchises started with multiple corporate owned locations, not just a single little rental location out of a bakery.
Kinda messed up isn't it, shareholders get to PAY ex-CEO to have someone else play CEO?
I wouldn't believe the "FLOAT" here is only 20-30 mil and wouldn't even entertain speculation of... If that were the case we wouldn't have dropped from .03, even with lack of interest (I own almost 2 million shares)
I'd bet the current float is between 400-700 million, which is still a very very nice number for a trip 0 stock! They did raise the AS to 850 million for a reason, but, at same time we haven't seen "massive" dilution, just lack of interest causing it to drop.
Maybe PennyStock can buy up 600,000,000 shares take those out of the OS...
Makes me laugh when anyone talks share buybacks in pinkies. 99.9995% of pinks fail, and probably 80% of pinks make their living off selling shares rather than real business, and all they do is recycle/dilute shells. If the guy really had $60k, he could easily rent space in 5-7 bakeries/buildings and already be on his way to franchising, why would he need a washed up shell with billions in shares pre-loaded with debt?
You think he's going to buy back 60k worth of stock? LOL...
$60k would open 5 little pizza joints so why in the world would he need to have the public company with wishy washy shareholders that turn him in to the SEC one week and then pump the stock the next?
Biodel Reports Second Quarter Fiscal Year 2011 Financial Results
4:00 pm ET 05/05/2011 - PR Newswire
DANBURY, Conn., May 5, 2011 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) today reported financial results for the quarter ended March 31, 2011.
Second Quarter Fiscal Year 2011 Financial Results
Biodel reported a net loss for the three months ended March 31, 2011 of $5.4 million, or $0.21 per share, compared to a net loss of $10.4 million, or $0.44 per share, for the same period in the prior year.
Research and development expenses were $2.9 million for the three months ended March 31, 2011, compared to $7.0 million for the same period in the prior year. The decrease of $4.1 million in expenses was primarily attributed to non-recurring events that occurred in the previous fiscal year including the conclusion of the Linjeta™ Phase 3 extension trials in February 2010 at a cost of $2.1 million; recombinant human insulin purchased at a cost of $1 million; professional fees of $0.7 million related to the 120 day safety report filing of Linjeta™ and follow-on questions from the FDA, and pen development costs of $0.4 million.
General and administrative expenses totaled $2.3 million for the three months ended March 31, 2011, compared to $3.4 million for the same period in the prior year. The decrease in general and administrative expenses was attributable to a decrease in personnel costs of $0.7 million as a result of lower headcount from 2010, and savings of $0.4 million in professional fees due to cost cutting measures.
Expenses for the three months ended March 31, 2011 and 2010 included $2.6 million in stock-based compensation expense related to options granted to employees and non-employee directors.
Biodel did not recognize any revenue during the three months ended March 31, 2011 or 2010.
At March 31, 2011, Biodel had cash and cash equivalents of $17.6 million and 26.5 million shares outstanding.
Business Review
•Biodel has selected two new recombinant human insulin-based formulation candidates, BIOD-105 and BIOD-107, for clinical development as ultra-rapid-acting mealtime insulins for the treatment of diabetes. Following recent discussions with the U.S. Food and Drug Administration, Biodel now plans to accelerate the timelines for clinical testing of these new formulations.
•Biodel has initiated a Phase 1 trial of BIOD-105 and BIOD-107 in a double-blind, three-period cross-over study in patients with Type 1 diabetes. This trial will evaluate the pharmacokinetic, pharmacodynamic and injection site tolerability profiles of the two experimental insulins relative to Humalog® when delivered by subcutaneous injection.
•In parallel with the Phase 1 clinical trial of BIOD-105 and BIOD-107 described above, investigators at Oregon Health and Sciences University will soon initiate a similar comparative study evaluating the use of these formulations and Humalog® when delivered by insulin pumps. The results of the two Phase 1 trials will be used to select the best formulation for Phase 2 clinical testing, planned to initiate later this year and Phase 3 clinical testing planned to initiate in 2012.
•Biodel recently named Dr. Brian Pereira as chairman of the company's board of directors. Dr. Pereira has been a board member since November 2007 and, as an experienced biotechnology executive, brings invaluable expertise to the company. Former chairman Dr. Charles Sanders will remain a member of Biodel's board.
Conference Call and Webcast Information
Biodel's senior management will host a conference call on May 5, 2011, beginning at 4:30 pm Eastern Daylight Saving Time, to discuss these results and provide a company update. Live audio of the conference call will be available to investors, members of the news media and the general public by dialing 1-877-303-8028 (United States) or 1-760-536-5167 (international). To access the call by live audio webcast, please log on to the investor section of the company's website at www.biodel.com. An archived version of the audio webcast will be available at Biodel's website.
About Biodel Inc.
Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes that may be safer, more effective and more convenient for patients. We develop our product candidates by applying our proprietary formulation technologies to existing drugs in order to improve their therapeutic profiles. For further information regarding Biodel, please visit the company's website at www.biodel.com.